Advertisement
"We are very pleased to reach 100% territorial coverage for CytoCare inAsia-Pacific. This new partnership culminates a great year for HealthRobotics' CytoCare adoption and unprecedented market success versus ourcompetition, on the heels of similar new partnerships signed this Summer andFall in Oceania, China, Taiwan, and South East Asia. In these difficulteconomic times and at a moment where our competitors are in retreat and totaldisarray, we have increased our lead in product superiority, expanded ourreach worldwide, and are now posed to reap benefits in years to come. Wewelcome BioRobotics to our family of strategic channel partners and lookforward to host them next week, along with more than twenty (20) worldwidepartners at Health Robotics' First Annual Partner Training in Trieste,Italy," stated Werner Rainer, Health Robotics' CEO.
Advertisement
CytoCare is the world's first and only robotic system designed for thesafe and sterile preparation of patient-specific hazardous IV Admixtures forChemotherapy, Monoclonal Antibody Therapy, and Gene Therapy. While othercompanies have for many years made promises of robotic IV automation productsand even showcased staged "smoke and mirrors" marketing demonstrations ofcompeting solutions that were supposed to exist as far back twenty years[1]ago, the fact remains that CytoCare is the only available solution thatcurrently exists anywhere in the world to automatically compound and prepareready-to-administer hazardous IV Admixtures, and that has been proven to workin a "live" hospital pharmacy environment, instead of just marketingbrochures and theatrical shows.
"We are delighted that Health Robotics has given us this greatopportunity as their exclusive strategic partner in our core market of Korea.CytoCare, the world's only real Oncology IV Admixtures Robot in existence,represents an ideal complement to BioRobotics' medical portfolio of OncologyRobotics' products and services, including Intuitive Surgical's daVinci(R)Surgery Robot. Just like Device Technologies Australia and PinnacleMed, I wasvery impressed with Health Robotics' technology and have received excellentreferences from other Asia-Pacific based daVinci(R) Surgery Robot'sdistribution partners, with whom we maintain regular contact. My contractnegotiation meetings with Gaspar DeViedma last week were very productive andled to the execution of this very important milestone for our company",stated Bum Kyo Lee, CEO of BioRobotics.
About Innomed/BioRobotics:
Founded in 1995, Innomed/BioRobotics is currently the leading medicalrobotics supplier and the second largest medical importing business in theRepublic of Korea with US $27M import volume during the year 2008. Thecompany originally started in the Aesthetic laser surgery and Cryosurgerymedical sectors and further expanded into robotic surgery in 2005. In only 4years since the launch of Oncology Robotics in its core market, BioRoboticshas already achieved twenty-four (24) installations of the daVinci(R)Surgical robot in the Republic of Korea. For more information, please visit:http://www.biorobotics.co.kr/
About Health Robotics:
Health Robotics is the global leading supplier of life-criticalintra-venous medication preparation, compounding, and dispensing Robots,providing healthcare facilities in four continents with robotics technologyand software automation solutions. The world-leading solutions CytoCare[hazardous IVs], i.v.STATION [non-hazardous IVs], i.v.SOFT [workflow engine]and the future development of TPNstation constitute the main building blocksof the company's vision to architect the I.V. Room of the Future on or beforethe year 2011. These Robots and software automation solutions have and willgreatly contribute to ease global hospitals' growing pressures to improvepatient safety through the effective and efficient production of sterile,accurate, and ready-to-administer IVs, to eliminate life-threateningdrug-exchange errors, to decrease other medication errors and sterilityrisks, and to work more efficiently, improve situational awareness of the IVMedication Management processes across the continuum of care, reduce thegenerational gap between rising patient volume/acuity and scarce pharmacypersonnel, increase throughput, reduce waste, and contain costs. For moreinformation, please visit http://www.health-robotics.com--------------------------------- [1] Am J Hosp Pharm 46(11): 2286-93 1989 For additional information, please contact: Health Robotics S.r.l Gaspar G. DeViedma, General Counsel Altmanstrasse 9A, Bozen, Sud-Tyrol, Italy-39100 USA: +1-609-980-7976 EUROPE: +39-346-963-4934 [email protected] BIOROBOTICS Bum Kyo Lee, CEO 5F 5-36 Hyochang-dong, Yongsan-ku, Seoul, Korea Phone: +82-27015266 [email protected]
SOURCE Health Robotics
